NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CRSP

CRISPR Therapeutics AG

Jun 24 • 04:00PM ET

46.78

Dollar change +1.23
Percentage change 2.70	%

Healthcare • Biotechnology • Switzerland • NASD

Peers: EDIT NTLA BEAM SGMO VRTX GILD BLUE ALLO CLLS ADPT

| Held by: ARKK ARKG XBI VXF IBB SCHA SCHM XT VHT LABU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.52	Insider Own	4.14%	Shs Outstand	86.36M	Perf Week	12.51%
Market Cap	4.04B	Forward P/E	-	EPS next Y	-4.46	Insider Trans	-2.36%	Shs Float	82.79M	Perf Month	24.65%
Enterprise Value	2.40B	PEG	-	EPS next Q	-1.43	Inst Own	69.15%	Short Float	24.81%	Perf Quarter	9.76%
Income	-385.66M	P/S	107.25	EPS this Y	-25.48%	Inst Trans	0.26%	Short Ratio	8.88	Perf Half Y	13.93%
Sales	37.67M	P/B	2.21	EPS next Y	18.02%	ROA	-16.75%	Short Interest	20.54M	Perf YTD	18.85%
Book/sh	21.18	P/C	2.17	EPS next 5Y	5.55%	ROE	-19.71%	52W High	63.68 -26.54%	Perf Year	-21.51%
Cash/sh	21.52	P/FCF	-	EPS past 3/5Y	- -	ROIC	-18.99%	52W Low	30.04 55.73%	Perf 3Y	-25.34%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-65.58% -33.62%	Gross Margin	-271.64%	Volatility	1.60% 2.45%	Perf 5Y	-29.41%
Dividend TTM	-	EV/Sales	63.73	EPS Y/Y TTM	-67.29%	Oper. Margin	-1259.20%	ATR (14)	2.36	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.64	Sales Y/Y TTM	-86.13%	Profit Margin	-1023.64%	RSI (14)	74.22	Recom	1.90
Dividend Gr. 3/5Y	- -	Current Ratio	15.64	EPS Q/Q	-11.02%	SMA20	14.61%	Beta	1.75	Target Price	77.21
Payout	-	Debt/Eq	0.12	Sales Q/Q	71.63%	SMA50	20.36%	Rel Volume	1.06	Prev Close	45.55
Employees	393	LT Debt/Eq	0.11	Earnings	May 06 AMC	SMA200	8.54%	Avg Volume	2.31M	Price	46.78
IPO	Oct 19, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.05% -86.25%	Trades		Volume	2,453,800	Change	2.70%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-25	Upgrade	Evercore ISI	In-line → Outperform	$60 → $99
Feb-12-25	Upgrade	TD Cowen	Sell → Hold	$35
Feb-03-25	Initiated	H.C. Wainwright	Buy	$65
Aug-06-24	Reiterated	Needham	Buy	$88 → $84
Aug-02-24	Initiated	Rodman & Renshaw	Buy	$90
Jun-28-24	Resumed	Guggenheim	Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-11-23	Downgrade	TD Cowen	Market Perform → Underperform	$30
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy	$82
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform	$75
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight	$72
Mar-21-23	Initiated	Bernstein	Mkt Perform	$44
Mar-17-23	Initiated	Bryan Garnier	Buy	$70
Mar-07-23	Initiated	Robert W. Baird	Neutral	$46
Oct-11-22	Initiated	Morgan Stanley	Underweight	$37
Aug-09-22	Downgrade	Barclays	Overweight → Equal Weight	$99 → $88
Jun-23-22	Downgrade	Evercore ISI	Outperform → In-line	$66 → $60
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$98

Show Previous Ratings

Jun-24-25 06:00PM	CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
04:06PM	CRISPR Therapeutics AG (CRSP): A Bull Case Theory (Insider Monkey)
04:17AM	The Best Stocks to Invest $1,000 in Right Now (Motley Fool)
Jun-21-25 06:10PM	2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts (Motley Fool)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
07:22AM	Loading…
Jun-19-25 07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
Jun-18-25 05:50PM	CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-10-25 05:50PM	CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts (Zacks)
Jun-06-25 09:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research) +8.53%
09:00AM	Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know (Zacks)
Jun-05-25 07:27PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
11:30AM	Loading…
11:30AM	CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
Jun-03-25 04:30AM	The Best Stocks to Invest $1,000 in Right Now (Motley Fool)
Jun-02-25 07:45AM	The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip (Motley Fool)
May-29-25 08:30AM	CRISPR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-26-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
May-21-25 12:25PM	Crispr Therapeutics call volume above normal and directionally bullish (TipRanks) -5.76%
09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-20-25 11:30PM	CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot Drug (Insider Monkey)
11:50AM	CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies (Zacks)
04:30AM	5 Monster Stocks to Hold for the Next 10 Years (Motley Fool)
03:43AM	CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy? (Motley Fool)
May-19-25 04:15PM	CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies (GlobeNewswire)
May-18-25 09:30AM	Prediction: This Beaten-Down Stock Could Double in The Next 5 Years (Motley Fool)
07:15AM	Loading…
May-16-25 07:15AM	CRSPR Stock Could Be Ready to Deliver on Its Massive Promise (MarketBeat) +6.77%
May-14-25 07:45AM	Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? (Motley Fool)
May-13-25 09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:10AM	2 Biotech Stocks That Are Screaming Buys in May (Motley Fool)
May-12-25 06:18AM	Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? (Motley Fool) +5.53%
May-10-25 05:12AM	3 Monster Stocks to Hold for the Next 10 Years (Motley Fool)
May-08-25 11:22AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) +5.52%
09:30AM	Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet (Zacks)
May-07-25 04:03PM	Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course (Seeking Alpha)
07:40AM	CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks (Zacks)
07:26AM	VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations (Zacks)
May-06-25 05:25PM	CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -11.86%
04:01PM	CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310 Targeting ANGPTL3 (GlobeNewswire)
11:59AM	VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened (Zacks)
May-05-25 09:50AM	Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains? (Zacks)
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-02-25 05:50PM	CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts (Zacks)
09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Apr-30-25 05:14AM	2 Beaten-Down Stocks With Incredible Upside Potential (Motley Fool)
Apr-29-25 07:51AM	Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? (Zacks)
Apr-25-25 11:59AM	CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-24-25 05:50PM	CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts (Zacks)
04:11PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
Apr-23-25 06:00PM	CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
08:33AM	Incoming Regulatory Tailwinds to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital (TipRanks)
Apr-21-25 09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Apr-20-25 09:15AM	5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years (Motley Fool)
Apr-17-25 06:00PM	CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Apr-12-25 02:45PM	3 Magnificent Stocks That Could Double or More by 2030 (Motley Fool)
Apr-11-25 03:45AM	Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? (Motley Fool) +14.71%
Apr-10-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know (Zacks)
Apr-09-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks) +11.58%
Apr-08-25 03:29PM	CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript) (Seeking Alpha)
Apr-07-25 08:09AM	4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street (Motley Fool)
07:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Apr-04-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Moves -0.03%: What You Should Know (Zacks)
Apr-03-25 09:30AM	Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March (Motley Fool)
08:00AM	CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
07:23AM	Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. (Zacks)
Mar-31-25 04:12PM	Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies' (Investor's Business Daily) -8.00%
03:25PM	Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today (Motley Fool)
10:10AM	Intellia Focuses on Pipeline Development Amid Stiff Competition (Zacks)
09:45AM	Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns (Investor's Business Daily)
09:03AM	The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics (Zacks)
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
07:01AM	Novo gains Lexicon obesity drug; CRISPR COO to step down (BioPharma Dive)
Mar-26-25 04:01PM	CRISPR Therapeutics Announces Transition of Chief Operating Officer (GlobeNewswire)
Mar-25-25 05:40PM	Is CRISPR Therapeutics AG (CRSP) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
11:03AM	CRISPR Therapeutics Set To Reach Previous Heights (SeekingAlpha)
09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Mar-22-25 04:04PM	2 Beaten-Down Stocks to Buy on the Dip (Motley Fool)
Mar-21-25 05:50PM	CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
08:00AM	As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy Point (Investor's Business Daily)
Mar-20-25 06:00PM	CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors (Zacks)
02:59AM	Intel And Crispr: 2 'Bond-Like' Option Trades Yielding 13%+ (SeekingAlpha)
Mar-19-25 06:10PM	2 No-Brainer Biotech Stocks to Buy Right Now (Fool)
02:39PM	Is CRISPR Therapeutics (CRSP) One of the Most Shorted Stocks in 2025? (Insider Monkey)
10:27AM	CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
09:41AM	CRISPR Therapeutics AG (CRSP): A Bull Case Theory (Insider Monkey)
Mar-18-25 10:41AM	CRISPR Therapeutics (CRSP): Among Top Stocks to Buy from Ark Invest's Portfolio (Insider Monkey)
Mar-14-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Mar-13-25 11:30AM	Why Is CRISPR Therapeutics (CRSP) Up 0.4% Since Last Earnings Report? (Zacks)
Mar-11-25 08:35AM	ElevateBio taps Amazons genAI tools to design CRISPR therapeutics (Pharmaceutical Technology)
Mar-03-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Feb-28-25 03:15AM	3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. (Motley Fool)
Feb-26-25 08:00AM	CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-24-25 10:00AM	2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street (Motley Fool)
Feb-23-25 01:34PM	CRISPR Therapeutics AG (CRSP): the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:01PM	CRISPR Therapeutics AG (CRSP): Among the Most Oversold Healthcare Stocks to Buy Now (Insider Monkey)

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Naimish	Chief Medical Officer	May 29 '25	Sale	35.94	3,932	141,316	6,068	May 30 05:00 PM
Kulkarni Samarth	Chief Executive Officer	Mar 21 '25	Sale	41.23	10,031	413,578	195,085	Mar 24 05:35 PM
Bruno Julianne	Chief Operating Officer	Mar 21 '25	Sale	41.23	1,714	70,668	10,544	Mar 24 05:35 PM
Prasad Raju	Chief Financial Officer	Mar 21 '25	Sale	41.23	2,197	90,582	16,767	Mar 24 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 21 '25	Sale	41.23	3,185	131,318	81,729	Mar 24 05:35 PM
Prasad Raju	Chief Financial Officer	Mar 17 '25	Sale	41.80	3,762	157,252	12,714	Mar 18 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Mar 11 '25	Sale	42.42	9,973	423,055	180,890	Mar 12 07:05 PM
Kulkarni Samarth	Chief Executive Officer	Mar 12 '25	Sale	43.32	4,462	193,294	185,428	Mar 12 07:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 11 '25	Sale	42.42	2,850	120,897	77,530	Mar 12 07:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 12 '25	Sale	43.32	1,116	48,345	78,664	Mar 12 07:05 PM
Bruno Julianne	Chief Operating Officer	Mar 11 '25	Sale	42.42	1,198	50,819	8,263	Mar 12 07:05 PM
Bruno Julianne	Chief Operating Officer	Mar 12 '25	Sale	43.32	190	8,231	8,508	Mar 12 07:05 PM
Greene John	Director	Feb 26 '25	Buy	44.85	7,000	313,948	7,000	Feb 28 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 19 '25	Sale	55.20	18,360	1,013,564	171,613	Feb 21 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 18 '25	Sale	55.05	11,640	640,782	196,901	Feb 19 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 19 '25	Sale	52.80	6,928	365,798	189,973	Feb 19 05:35 PM
Bruno Julianne	Chief Operating Officer	Feb 19 '25	Sale	52.80	333	17,582	7,062	Feb 19 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 18 '25	Sale	53.85	9,595	516,691	73,002	Feb 19 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 19 '25	Sale	52.80	1,947	102,802	74,880	Feb 19 05:35 PM
Samarth Kulkarni	Officer	Feb 18 '25	Proposed Sale	52.22	45,000	2,349,900		Feb 18 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Dec 24 '24	Option Exercise	16.21	13,751	222,904	195,291	Dec 27 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Dec 02 '24	Sale	55.10	15,000	826,564	181,540	Dec 04 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Nov 11 '24	Sale	55.62	30,000	1,668,678	196,540	Nov 13 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Oct 14 '24	Sale	46.28	1,089	50,399	62,597	Oct 15 06:00 PM
Kulkarni Samarth	Chief Executive Officer	Oct 14 '24	Sale	46.28	4,293	198,680	226,540	Oct 15 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRSP

CRISPR Therapeutics AG

Upgrade your FINVIZ experience